Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 2/20 | 0.53 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.53 |
| ▸ | ALB | P02768 | 1/20 | 0.53 |
| ▸ | ADCY5 | O95622 | 6/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 5/20 | 0.38 |
| ▸ | PNP | P00491 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30827047 | 0.88 | PDE4D (0.55) | PDE4DNR1I2ALBADCY5LMNA | |
| SCHEMBL3040267 | 0.88 | PDE4D (0.55) | PDE4DNR1I2ALBADCY5LMNA | |
| SCHEMBL31454794 | 0.85 | NR1I2 (0.67) | PDE4DNR1I2ALBADCY5LMNA | |
| SCHEMBL6694128 | 0.85 | NR1I2 (0.67) | PDE4DNR1I2ALBADCY5LMNA | |
| SCHEMBL13789990 | 0.85 | NR1I2 (0.67) | PDE4DNR1I2ALBADCY5LMNA | |
| SCHEMBL6764237 | 0.85 | NR1I2 (0.67) | PDE4DNR1I2ALBADCY5LMNA | |
| SCHEMBL31454816 | 0.85 | NR1I2 (0.67) | PDE4DNR1I2ALBADCY5LMNA | |
| SCHEMBL7654778 | 0.85 | NR1I2 (0.67) | PDE4DNR1I2ALBADCY5LMNA | |
| SCHEMBL7099022 | 0.85 | NR1I2 (0.67) | PDE4DNR1I2ALBADCY5LMNA | |
| SCHEMBL14048997 | 0.85 | NR1I2 (0.67) | PDE4DNR1I2ALBADCY5LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238323-A1 | MODIFIED NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS FOR CORONA AND OTHER VIRUSES | EMORY UNIVERSITY | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238323-A1 | MODIFIED NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS FOR CORONA AND OTHER VIRUSES | MTAP, PNP, SARS1 | PDE4D 1024/4885NR1I2 3733/4885ALB 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.